Pharma Site Services Limited 11078966 false 2024-10-01 2025-09-30 2025-09-30 The principal activity of the company is Repair Services Digita Accounts Production Advanced 6.30.9574.0 true 11078966 2024-10-01 2025-09-30 11078966 2025-09-30 11078966 core:CurrentFinancialInstruments core:WithinOneYear 2025-09-30 11078966 bus:Micro-entities 2024-10-01 2025-09-30 11078966 bus:AuditExemptWithAccountantsReport 2024-10-01 2025-09-30 11078966 bus:FilletedAccounts 2024-10-01 2025-09-30 11078966 bus:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 11078966 bus:RegisteredOffice 2024-10-01 2025-09-30 11078966 bus:Director1 2024-10-01 2025-09-30 11078966 bus:Director2 2024-10-01 2025-09-30 11078966 bus:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 11078966 countries:AllCountries 2024-10-01 2025-09-30 11078966 2023-10-01 2024-09-30 11078966 2024-09-30 11078966 core:CurrentFinancialInstruments core:WithinOneYear 2024-09-30 iso4217:GBP xbrli:pure

Registration number: 11078966

Pharma Site Services Limited

Unaudited Filleted Financial Statements

for the Year Ended 30 September 2025

image-name
 

Pharma Site Services Limited

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

2

 

Pharma Site Services Limited

Company Information

Directors

A Thomson

D J O'Malley

Registered office

Lloyds Bank House Lloyds Bank House
Bellingham
Hexham
Northumberland
NE48 2AZ

Accountants

TyneRede Accountancy Ltd
Chartered Certified Accountant
Lloyds Bank House
Bellingham
Hexham
Northumberland
NE48 2AZ

 

Pharma Site Services Limited

(Registration number: 11078966)
Balance Sheet as at 30 September 2025

2025
£

2024
£

Fixed assets

119,161

124,757

Current assets

95,226

134,772

Prepayments and accrued income

1,313

803

Creditors: Amounts falling due within one year

(34,625)

(63,653)

Net current assets

61,914

71,922

Total assets less current liabilities

181,075

196,679

Accruals and deferred income

(975)

(950)

 

180,100

195,729

Capital and reserves

180,100

195,729

1

General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
Lloyds Bank House Lloyds Bank House
Bellingham
Hexham
Northumberland
NE48 2AZ
United Kingdom

These financial statements were authorised for issue by the Board on 22 May 2026.

Basis of preparation

The financial statements have been prepared under the historical cost convention and in accordance with FRS 105 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

2

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2024 - 2).

3

Financial commitments, guarantees and contingencies

Amounts not provided for in the balance sheet

The total amount of financial commitments not included in the balance sheet is £Nil (2024 - £Nil).

For the financial year ending 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

 

Pharma Site Services Limited

(Registration number: 11078966)
Balance Sheet as at 30 September 2025

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 22 May 2026 and signed on its behalf by:
 

.........................................
D J O'Malley
Director